BRAF (gene)

BRAF is a human is_associated_with::gene that makes a is_associated_with::protein called B-Raf. The gene is also referred to as is_associated_with::proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf.

The B-Raf protein is involved in sending signals inside cells, which are involved in directing is_associated_with::cell growth. In 2002, it was shown to be faulty (mutated) in some human is_associated_with::cancers.

Certain other inherited BRAF mutations cause birth defects.

Drugs that treat cancers driven by BRAF mutations have been developed. Two of these drugs, is_associated_with::vemurafenib and is_associated_with::dabrafenib are approved by FDA for treatment of late-stage melanoma. Vemurafenib was the first drug to come out of is_associated_with::fragment-based drug discovery.

Function
B-Raf is a member of the is_associated_with::Raf kinase family of growth is_associated_with::signal transduction is_associated_with::protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects is_associated_with::cell division, differentiation, and secretion.

Structure
B-Raf is a 766-is_associated_with::amino acid, regulated is_associated_with::signal transduction is_associated_with::serine/threonine-specific protein kinase. Broadly speaking, it is composed of three conserved domains characteristic of the Raf kinase family: conserved region 1 (CR1), a Ras-GTP-binding self-regulatory domain, conserved region 2 (CR2), a is_associated_with::serine-rich hinge region, and conserved region 3 (CR3), a catalytic is_associated_with::protein kinase domain that phosphorylates a is_associated_with::consensus sequence on protein substrates. In its active conformation, B-Raf forms dimers via hydrogen-bonding and electrostatic interactions of its kinase domains.

CR1
Conserved region 1 autoinhibits B-Raf's kinase domain (CR3) so that B-Raf signaling is regulated rather than constitutive. Residues 155–227 make up the Ras-binding domain (RBD), which binds to Ras-GTP's effector domain to release CR1 and halt kinase inhibition. Residues 234–280 comprise a is_associated_with::phorbol ester/DAG-binding is_associated_with::zinc finger motif that participates in B-Raf membrane docking after Ras-binding.

CR2
Conserved Region 2 (CR2) provides a flexible linker that connects CR1 and CR3 and acts as a hinge.

CR3


Conserved Region 3 (CR3), residues 457–717, makes up B-Raf's enzymatic kinase domain. This largely conserved structure is bi-lobal, connected by a short hinge region. The smaller N-lobe (residues 457–530) is primarily responsible for ATP binding while the larger C-lobe (residues 535–717) binds substrate proteins. The active site is the cleft between the two lobes, and the catalytic Asp576 residue is located on the C-lobe, facing the inside of this cleft.

Subregions
P-Loop

The P-loop of B-Raf (residues 464–471) stabilizes the non-transferable is_associated_with::phosphate groups of ATP during enzyme ATP-binding. Specifically, S467, F468, and G469 backbone is_associated_with::amides hydrogen-bond to the β-phosphate of ATP to anchor the molecule. B-Raf functional motifs have been determined by analyzing the homology of PKA analyzed by Hanks and Hunter to the B-Raf kinase domain.

Nucleotide-Binding Pocket

V471, C532, W531, T529, L514, and A481 form a hydrophobic pocket within which the adenine of ATP is anchored through Van der Waals attractions upon ATP binding.

Catalytic Loop

Residues 574–581 compose a section of the kinase domain responsible for supporting the transfer of the γ-phosphate of ATP to B-Raf's protein substrate. In particular, D576 acts as a proton acceptor to activate the nucleophilic hydroxyl oxygen on substrate serine or threonine residues, allowing the phosphate transfer reaction to occur mediated by base-catalysis.

DFG Motif

D594, F595, and G596 compose a motif central to B-Raf's function in both its inactive and active state. In the inactive state, F595 occupies the nucleotide-binding pocket, prohibiting ATP from entering and decreasing the likelihood of enzyme catalysis. In the active state, D594 chelates the is_associated_with::divalent is_associated_with::magnesium is_associated_with::cation that stabilizes the β- and γ-phosphate groups of ATP, orienting the γ-phosphate for transfer.

Activation Loop

Residues 596–600 form strong hydrophobic interactions with the P-loop in the inactive conformation of the kinase, locking the kinase in its inactive state until the activation loop is phosphorylated, destabilizing these interactions with the presence of negative charge. This triggers the shift to the active state of the kinase. Specifically, L597 and V600 of the activation loop interact with G466, F468, and V471 of the P-loop to keep the kinase domain inactive until it is phosphorylated.

Enzymology
B-Raf is a is_associated_with::serine/threonine-specific protein kinase. As such, it catalyzes the phosphorylation of is_associated_with::serine and is_associated_with::threonine residues in a is_associated_with::consensus sequence on target proteins by ATP, yielding ADP and a phosphorylated protein as products. Since it is a highly regulated is_associated_with::signal transduction kinase, B-Raf must first bind Ras-GTP before becoming active as an enzyme. Once B-Raf is activated, a conserved protein kinase catalytic core phosphorylates protein substrates by promoting the nucleophilic attack of the activated substrate serine or threonine is_associated_with::hydroxyl oxygen atom on the γ-phosphate group of ATP through is_associated_with::bimolecular nucleophilic substitution.

Relieving CR1 autoinhibition
The kinase (CR3) domain of human is_associated_with::Raf kinases is inhibited by two mechanisms: autoinhibition by its own regulatory Ras-GTP-binding CR1 domain and a lack of post-translational phosphorylation of key serine and is_associated_with::tyrosine residues (S338 and Y341 for c-Raf) in the CR2 hinge region. During B-Raf activation, the protein's autoinhibitory CR1 domain first binds Ras-GTP's effector domain to the CR1 Ras-binding domain (RBD) to release the kinase CR3 domain like other members of the human Raf kinase family. The CR1-Ras interaction is later strengthened through the binding of the is_associated_with::cysteine-rich subdomain (CRD) of CR1 to Ras and membrane is_associated_with::phospholipids. Unlike A-Raf and is_associated_with::C-Raf, which must be phosphorylated on hydroxyl-containing CR2 residues before fully releasing CR1 to become active, B-Raf is constituitively phosphorylated on CR2 S445. This allows the negatively charged phosphoserine to immediately repel CR1 through steric and electrostatic interactions once the regulatory domain is unbound, freeing the CR3 kinase domain to interact with substrate proteins.

CR3 domain activation
After the autoinhibitory CR1 regulatory domain is released, B-Raf's CR3 kinase domain must change to its ATP-binding active conformer before it can catalyze protein phosphorylation. In the inactive conformation, F595 of the DFG motif blocks the hydrophobic is_associated_with::adenine binding pocket while activation loop residues form hydrophobic interactions with the P-loop, stopping ATP from accessing its binding site. When the activation loop is phosphorylated, the negative charge of the phosphate is unstable in the hydrophobic environment of the P-loop. As a result, the activation loop changes conformation, stretching out across the C-lobe of the kinase domain. In this process, it forms stabilizing β-sheet interactions with the β6 strand. Meanwhile, the phosphorylated residue approaches K507, forming a stabilizing salt bridge to lock the activation loop into place. The DFG motif changes conformation with the activation loop, causing F595 to move out of the adenine nucleotide binding site and into a hydrophobic pocket bordered by the αC and αE helices. Together, DFG and activation loop movement upon phosphorylation open the ATP binding site. Since all other substrate-binding and catalytic domains are already in place, phosphorylation of the activation loop alone activates B-Raf's kinase domain through a chain reaction that essentially removes a lid from an otherwise-prepared active site.

Mechanism of catalysis


To effectively catalyze protein phosphorylation via the bimolecular substitution of serine and threonine residues with ADP as a is_associated_with::leaving group, B-Raf must first bind ATP and then stabilize the is_associated_with::transition state as the γ-phosphate of ATP is transferred.

ATP binding
B-Raf binds ATP by anchoring the adenine nucleotide in a is_associated_with::nonpolar pocket (yellow, Figure 1) and orienting the molecule through hydrogen-bonding and electrostatic interactions with phosphate groups. In addition to the P-loop and DFG motif phosphate binding described above, K483 and E501 play key roles in stabilizing non-transferable phosphate groups. The positive charge on the primary is_associated_with::amine of K483 allows it to stabilize the negative charge on ATP α- and β-phosphate groups when ATP binds. When ATP is not present, the negative charge of the E501 is_associated_with::carboxyl group balances this charge.

Phosphorylation
Once ATP is bound to the B-Raf kinase domain, D576 of the catalytic loop activates a substrate hydroxyl group, increasing its nucleophilicity to kinetically drive the phosphorylation reaction while other catalytic loop residues stabilize the transition state.(Figure 2). N581 chelates the divalent magnesium cation associated with ATP to help orient the molecule for optimal substitution. K578 neutralizes the negative charge on the γ-phosphate group of ATP so that the activated ser/thr substrate residue won't experience as much electron-electron repulsion when attacking the phosphate. After the phosphate group is transferred, ADP and the new phosphoprotein are released.

Inhibitors
Since constitutively active B-Raf mutants commonly cause cancer (see Clinical Significance) by excessively signaling cells to grow, inhibitors of B-Raf have been developed for both the inactive and active conformations of the kinase domain as cancer therapeutic candidates.

Sorafenib


BAY43-9006 (is_associated_with::Sorafenib, Nexavar)is a V600E is_associated_with::mutant B-Raf and is_associated_with::C-Raf inhibitor approved by the FDA for the treatment of primary liver and kidney cancer. Bay43-9006 disables the B-Raf kinase domain by locking the enzyme in its inactive form. The inhibitor accomplishes this by blocking the ATP binding pocket through high-affinity for the kinase domain. It then binds key activation loop and DFG motif residues to stop the movement of the activation loop and DFG motif to the active conformation. Finally, a trifluoromethyl phenyl moiety sterically blocks the DFG motif and activation loop active conformation site, making it impossible for the kinase domain to shift conformation to become active.

The distal pyridyl ring of BAY43-9006 anchors in the hydrophobic nucleotide-binding pocket of the kinase N-lobe, interacting with W531, F583, and F595. The hydrophobic interactions with catalytic loop F583 and DFG motif F595 stabilize the inactive conformation of these structures, decreasing the likelihood of enzyme activation. Further hydrophobic interaction of K483, L514, and T529 with the center phenyl ring increase the affinity of the kinase domain for the inhibitor. Hydrophobic interaction of F595 with the center ring as well decreases the energetic favorability of a DFG conformation switch further. Finally, polar interactions of BAY43-9006 with the kinase domain continue this trend of increasing enzyme affinity for the inhibitor and stabilizing DFG residues in the inactive conformation. E501 and C532 hydrogen bond the is_associated_with::urea and pyridyl groups of the inhibitor respectively while the is_associated_with::urea is_associated_with::carbonyl accepts a hydrogen bond from D594's backbone is_associated_with::amide nitrogen to lock the DFG motif in place.

The trifluoromethyl phenyl moiety cements the thermodynamic favorability of the inactive conformation when the kinase domain is bound to BAY43-9006 by sterically blocking the hydrophobic pocket between the αC and αE helices that the DFG motif and activation loop would inhabit upon shifting to their locations in the active conformation of the protein.

Vemurafenib


PLX4032 (is_associated_with::Vemurafenib) is a V600 is_associated_with::mutant B-Raf inhibitor approved by the FDA for the treatment of late-stage is_associated_with::melanoma. Unlike BAY43-9006, which inhibits the inactive form of the kinase domain, Vemurafenib inhibits the active "DFG-in" form of the kinase, firmly anchoring itself in the ATP-binding site. By inhibiting only the active form of the kinase, Vemurafenib selectively inhibits the proliferation of cells with unregulated B-Raf, normally those that cause is_associated_with::cancer.

Since Vemurafenib only differs from its precursor, PLX4720, in a is_associated_with::phenyl ring added for pharmacokinetic reasons, PLX4720's mode of action is equivalent to Vemurafenib's. PLX4720 has good affinity for the ATP binding site partially because its anchor region, a 7-azais_associated_with::indole bicyclic, only differs from the natural adenine that occupies the site in two places where nitrogen atoms have been replaced by carbon. This enables strong intermolecular interactions like N7 hydrogen bonding to C532 and N1 hydrogen bonding to Q530 to be preserved. Excellent fit within the ATP-binding hydrophobic pocket (C532, W531, T529, L514, A481) increases binding affinity as well. is_associated_with::Ketone linker hydrogen bonding to water and difluoro-phenyl fit in a second hydrophobic pocket (A481, V482, K483, V471, I527, T529, L514, and F583) contribute to the exceptionally high binding affinity overall. Selective binding to active Raf is accomplished by the terminal propyl group that binds to a Raf-selective pocket created by a shift of the αC helix. Selectivity for the active conformation of the kinase is further increased by a pH-sensitive deprotonated sulfonamide group that is stabilized by hydrogen bonding with the backbone peptide NH of D594 in the active state. In the inactive state, the inhibitor's sulfonamide group interacts with the backbone is_associated_with::carbonyl of that residue instead, creating repulsion. Thus, Vemurafenib binds preferentially to the active state of B-Raf's kinase domain.

Clinical significance
Mutations in the BRAF gene can cause disease in two ways. First, mutations can be inherited and cause birth defects. Second, mutations can appear later in life and cause cancer, as an is_associated_with::oncogene.

Inherited mutations in this gene cause is_associated_with::cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance.

Mutations in this gene have been found in cancers, including is_associated_with::non-Hodgkin lymphoma, is_associated_with::colorectal cancer, malignant is_associated_with::melanoma, papillary thyroid carcinoma, is_associated_with::non-small-cell lung carcinoma, and is_associated_with::adenocarcinoma of the lung.

The V600E mutation of the BRAF gene has been associated with is_associated_with::hairy cell leukemia in numerous studies and has been suggested for use in screening for is_associated_with::Lynch syndrome to reduce the number of patients undergoing unnecessary is_associated_with::MLH1 sequencing.

Mutants
More than 30 mutations of the BRAF gene associated with human cancers have been identified. The frequency of BRAF mutations varies widely in human cancers, from more than 80% in is_associated_with::melanomas and nevi, to as little as 0–18% in other is_associated_with::tumors, such as 1–3% in lung cancers and 5% in is_associated_with::colorectal cancer. In 90% of the cases, thymine is substituted with adenine at nucleotide 1799. This leads to valine (V) being substituted for by glutamate (E) at codon 600 (now referred to as V600E) in the activation segment that has been found in human cancers. This mutation has been widely observed in is_associated_with::papillary thyroid carcinoma, colorectal cancer, melanoma and is_associated_with::non-small-cell lung cancer. BRAF-V600E mutation are present in 57% of Langerhans cell histiocytosis patients. The V600E mutation is a likely driver mutation in 100% of cases of is_associated_with::hairy cell leukaemia. High frequency of BRAF V600E mutations have been detected in ameloblastoma, a benign but locally infiltrative odontogenic neoplasm. The V600E mutation may also be linked, as a single-driver mutation (a genetic 'smoking gun') to certain cases of papillary is_associated_with::craniopharyngioma development.

Other mutations which have been found are R461I, I462S, G463E, G463V, G465A, G465E, G465V, G468A, G468E, N580S, E585K, D593V, F594L, G595R, L596V, T598I, V599D, V599E, V599K, V599R, V600K, A727V, etc. and most of these mutations are clustered to two regions: the glycine-rich P loop of the N lobe and the activation segment and flanking regions. These mutations change the activation segment from inactive state to active state, for example in the previous cited paper it has been reported that the aliphatic side chain of Val599 interacts with the phenyl ring of Phe467 in the P loop. Replacing the medium-sized hydrophobic Val side chain with a larger and charged residue as found in human cancer(Glu, Asp, Lys, or Arg) would be expected to destabilize the interactions that maintain the DFG motif in an inactive conformation, so flipping the activation segment into the active position. Depending on the type of mutation the kinase activity towards MEK may also vary. Most of the mutants stimulate enhanced B-Raf is_associated_with::kinase activity toward MEK. However, a few mutants act through a different mechanism because although their activity toward MEK is reduced, they adopt a conformation that activates wild-type C-RAF, which then signals to ERK.

BRAF-V600E

 * BRAF V600E is a determinant of sensitivity to is_associated_with::proteasome inhibitors. Vulnerability to is_associated_with::proteasome inhibitors is dependent on persistent BRAF signaling, because BRAF-V600E blockade by is_associated_with::PLX4720 reversed sensitivity to is_associated_with::carfilzomib in BRAF-mutant colorectal cancer cells. is_associated_with::Proteasome inhibition might represent a valuable targeting strategy in BRAF V600E-mutant colorectal tumors.

BRAF inhibitors in the clinic
As mentioned above, some pharmaceutical firms are developing specific inhibitors of mutated B-raf protein for anticancer use because BRAF is a well-understood, high yield target. is_associated_with::Vemurafenib (RG7204 or PLX4032), licensed by the US is_associated_with::Food and Drug Administration as Zelboraf for the treatment of metastatic melanoma in August 2011, is the current state-of-the-art example for why active B-Raf inhibitors are being pursued as drug candidates. Vemurafenib is biochemically interesting as a mechanism to target cancer due to its high efficacy and selectivity. In Phase II and Phase III clinical trials, B-Raf not only increased metastatic melanoma patient chance of survival but raised the response rate to treatment from 7-12% to 53% in the same amount of time compared to the former best chemotherapeutic treatment: dacarbazine. In spite of the drug's high efficacy, 20% of tumors still develop resistance to the treatment. In mice, 20% of tumors become resistant after 56 days. While the mechanisms of this resistance are still disputed, some hypotheses include the overexpression of B-Raf to compensate for high concentrations of Vemurafenib and upstream upregulation of growth signaling.

More general B-is_associated_with::raf inhibitors include is_associated_with::GDC-0879, is_associated_with::PLX-4720, is_associated_with::Sorafenib Tosylate. is_associated_with::dabrafenib, is_associated_with::LGX818

Interactions
BRAF (gene) has been shown to interact with:
 * is_associated_with::AKT1,
 * is_associated_with::C-Raf,
 * is_associated_with::HRAS, and
 * is_associated_with::YWHAB.